Multimedia
VIDEO - Future is bio-pharma: Kiran Mazumdar-Shaw
Dr Kiran Mazumdar Shaw, Executive Chairperson, Biocon Ltd and Biocon Biologics is unhappy with the PLI scheme as the Indian pharma industry gains traction post-Covid-19, the government has offered a series of PLI schemes. She says the schemes are skewed towards generic companies.
It does not take into account the higher investment and a longer gestation period that a biopharmaceuticals company needs to give returns on the investment. She feels that biopharmaceuticals—despite it being the future of healthcare—is not getting the recognition it deserves. The schemes are short-sighted.
Also Read
-
Tata Technologies FY24 profit surges 9% at ₹679 cr; revenue grows 16%
-
WhatsApp India bans 2.2 crore accounts in Jan-March
-
Titan Q4 profit rises 5% to ₹771 crore
-
Adani Green Q4 profit drops 39% to ₹310 cr
-
Godrej Properties Q4 profit up 14%; revenue down 13% to ₹1,426 cr